Innovation in Pain Management
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Journal Official Journal of the World Medical Association, Inc
ISSN 2256-0580 COVID-19 World Medical Journal Official Journal of The World Medical Association, Inc. Nr. 2, April 2020 vol. 66 Contents Editorial . 1 COVID-19: the Asian Perspective . 2 The Corona Virus Outbreak on South African Medical Schemes . 13 Reform Proceeding of Organ Donation and Transplantation System in China . 15 The Impact of Climate Change on Health . 19 Physical Activities of Doctors in Rivers State, Southern Nigeria . 21 Palliative Care: What, Who, When, How? . 25 The “Normalization” of Euthanasia in Canada: the Cautionary Tale Continues . 28 Appeal for Policy Promotion . 38 This Month Consider Indoor Air Health . 40 Singapore Medical Association – sixty years on . iii World Medical Association Officers, Chairpersons and Officials Dr . Miguel Roberto JORGE Dr . David Barbe Dr . Leonid EIDELMAN Prof . Dr . Frank Ulrich WMA President, WMA President-Elect, WMA Immediate Past-President MONTGOMERY Brazilian Medical Association American Medical Association Israeli Medical Association Chairperson of Council Rua-Sao Carlos do Pinhal 324, AMA Plaza, 330 N. Wabash, Suite 2 Twin Towers, 35 Jabotinsky St., Bundesärztekammer CEP-01333-903 Sao Paulo-SP 39300 P.O. Box 3566 Herbert-Lewin-Platz 1 (Wegelystrasse) Brazil 60611-5885 Chicago, Illinois 52136 Ramat-Gan 10623 Berlin United States Israel Germany Dr . Otmar KLOIBER Dr . Mari MICHINAGA Dr . Ravindra Sitaram Dr . Andreas RUDKJØBING Secretary General WMA Vice-Chairperson of Council WANKHEDKAR WMA Chairperson of the Medical World Medical Association Japan Medical Association WMA Treasurer Ethics Committee 13 chemin du Levant 2-28-16 Honkomagome Indian Medical Association Danish Medical Association 01212 Ferney-Voltaire 113-8621 Bunkyo-ku, Tokyo Indraprastha Marg Kristianiagade 12 France Japan 110 002 New Delhi 2100 Copenhagen 0 India Denmark Dr . -
Is Oral Morphine Still the First Choice Opioid for Moderate to Severe
Review Palliative Medicine 25(5) 402–409 ! The Author(s) 2010 Is oral morphine still the first choice Reprints and permissions: sagepub.co.uk/journalsPermissions.nav opioid for moderate to severe cancer DOI: 10.1177/0269216310392102 pain? A systematic review within the pmj.sagepub.com European Palliative Care Research Collaborative guidelines project Augusto Caraceni Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Italy Alessandra Pigni Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Italy Cinzia Brunelli Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Italy Abstract The aim of this systematic review was to evaluate the evidence that oral morphine can be recommended as the first choice opioid in the treatment of moderate to severe cancer pain in updating the European Association for Palliative Care opioid recommendations. A systematic literature review was performed to update the 2007 Cochrane review ‘Oral morphine for cancer pain’. The literature search was conducted on MedLine, EMBASE and Cochrane Central Register of Controlled Trials databases. The search strategy, limited in time (from 1 July 2006 to 31 October 2009), was aimed to be as extensive as possible using both text words and MeSH/EMTREE terms; a hand search of the reference lists of identified papers was also performed. Randomized clinical trials, containing data on efficacy and/or side effects of morphine, were identified. Among the papers retrieved from the cited databases and the Cochrane review, 17 eligible studies, for a total of 2053 patients, and a meta-analysis were selected. These studies do not add significant information to the previous Cochrane review confirming the limitation of efficacy and tolerability data on opioid-naı¨ve and non-selected populations of cancer patients treated with morphine and suggesting that oral morphine, oxycodone and hydromorphone have similar efficacy and toxicity in this patient population. -
Pcf5 Palliative Care Formulary
PCF5 PALLIATIVE CARE FORMULARY Published by palliativedrugs.com Ltd. Palliativedrugs.com Ltd Hayward House Study Centre Nottingham University Hospitals NHS Trust, City Campus Nottingham NG5 1PB United Kingdom www.palliativedrugs.com # palliativedrugs.com Ltd 2014 The moral rights of the editors have been asserted. PCF4þ ePDF 2013 PCF4þ ePDF 2012 PCF4 2011, reprinted 2012 (twice), 2013 PCF3 2007, reprinted 2008, 2009 PCF2 2002, reprinted 2003 PCF1 1998 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission in writing of palliativedrugs.com Ltd or as expressly permitted by law, or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to [email protected] or by ordinary mail to the above address. British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library. ISBN 978-0-9552547-9-6 Typeset by OKS Prepress Services Private Ltd, Chennai, India Printed by Halstan Printing Group, Amersham, UK DISCLAIMER Every effort has been made to ensure the accuracy of this text, and that the best information available has been used. However, palliativedrugs.com Ltd neither represents nor guarantees that the practices described herein will, if followed, ensure safe and effective patient care. The recommendations contained in this book reflect the editors’ judgement regarding the state of general knowledge and practice in the field as of the date of publication. Information in a book of this type can never be all-inclusive, and therefore will not cover every eventuality. -
Acetate, Administration Of, in Parenteral Nutrition Support, 102
327 INDEX Acetate, administration of, in parenteral 50-52 nutrition support, 102 diagnostic tests for, 52-53 Acetominophen, 211, 213 prevention of, 55-58 Acidosis, correction of, with parenteral Aminoglycosides, nephro- and ototoxicity of, nutrition support, 102 11 Actinomycin D, 89 Amekacin, nephrotoxicity of, 11 Acylampicillins, toxic effects of, 10-11 Amphotericin B, chemical structure of, 16 Adenine diphosphate, effect of aspirin on, 212 combined with 5-flucytosine, for crypto- Adolescence, cancer statistics for, 291, 292 coccosis, 30 concept of body image during, 284-85 for aspergillosis, 27 coping strategies for disease during, 289-90 for candidiasis, 23, 24 current approach to cancer care during, for coccidioidomycosis, 31 281-82 for histoplasmosis, 32 emotional and physical development during, for mucormycosis, 28 282-86 for trichosporon infection, 31 general principles for management of cancer interaction of, with granulocyte trans- during, fusions, 73 activities, 298-99 pharmacokinetics of, 17 bereavement follow-up, 305 toxic effects of, 19 birth control, 300 Analgesic(s). See also names of specific drugs diagnosis, 293 classifications of, 206, 207 discussion of diagnosis, 293-98 controversial,231-33 financial expenses, 301-02 equianalgesic comparison of, 222-25 home care, 302-03 guidelines for selection and use of, 208 school program, 299-300 mechanisms of action by, 208-11 sibling care, 300-01 narcotic, supportive care, 298 cardiovascular effects of, 221 psychological impact of illness and hospital chemical classifications of, 216, 218 ization during, 287-89 effects of, on central nervous system, Adriamycin, emesis caused by, 89 219 hematopoietic effects of, 179 effects of, on endocrine system, 221 Aged. -
Opioid Managementtm a Medical Journal for Proper and Adequate Use
JOURNAL OF OPIOID MANAGEMENT OPIOID OF JOURNAL Journal of Opioid ManagementTM A medical journal for proper and adequate use Volume 3, Number 1 JANUARY/FEBRUARY 2007 ISSN 1551-7489 Official Journal of Opioid Management Society CONTENTS n GUEST EDITORIAL Patterns of illicit drug use and retention in a Can we continue to do business as usual? . 5 methadone program: A longitudinal study. 27 B. Eliot Cole, MD, MPA Ingrid Davstad, MA Marlene Stenbacka, PhD n OPIOID NEWS AND EVENTS Anders Leifman, MSE Calendar . 8 Olof Beck, PhD News briefs . 9 Seher Korkmaz, MD, PhD Anders Romelsjö, MD, PhD n PHARMACY PERSPECTIVE A randomized, open-label, multicenter trial Opioid administration for acute abdominal comparing once-a-day AVINZA® (morphine JANUARY/FEBRUARY 2007 pain in the pediatric emergency department . 11 sulfate extended-release capsules) versus twice- Adi Klein-Kremer, MD a-day OxyContin® (oxycodone hydrochloride Ran D. Goldman, MD controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: n LEGAL PERSPECTIVE Improved physical functioning in the ACTION trial . 35 Medicolegal rounds: Medicolegal issues and alleged breaches of standards of medical care Richard L. Rauck, MD in a patient motor vehicle accident allegedly Stephen A. Bookbinder, MD related to chronic opioid analgesic therapy . 16 Timothy R. Bunker, MD Christopher D. Alftine, MD David A. Fishbain, MD, FAPA Steven Gershon, MD John E. Lewis, PhD Egbert de Jong, MD Brandly Cole, PsyD Andres Negro-Vilar, MD, PhD Renné Steele Rosomoff, BSN, MBA Richard Ghalie, MD Hubert L. Rosomoff, MD, DMedSc, FAAPM n LITERATURE REVIEWS n ORIGINAL ARTICLES Buprenorphine: A unique opioid with broad Morphine prescription in end-of-life care and clinical applications . -
Ebook Download Cicely Saunders: the Founder of the Modern
CICELY SAUNDERS: THE FOUNDER OF THE MODERN HOSPICE MOVEMENT PDF, EPUB, EBOOK Shirley Du Boulay, Marianne Rankin | 320 pages | 01 Sep 2007 | SPCK Publishing | 9780281058891 | English | London, United Kingdom Remembering Dame Cicely Saunders: Founder of Hospice Nursing Times. As a building can allow one to shelter in space, it can also allow one to shelter in time. For Saunders, the importance of St. In the brochure, a specific section is dedicated to emphasising the modern scientific medicine that will be practiced, and improved, at St. As outlined in The Need , research into pain and other symptoms specific to the terminally ill was to be an important aspect of the work conducted at St. To this end, Saunders specifically incorporated a post-mortem room and wrote to the Borough Coroner to ascertain any special requirements he might have. By including this room, Cicely provided the space to conduct evidence-based research — important for a fledgling medical field to gain acceptance and authority in its treatments from medical colleagues and others. These studies showed that pain described by patients could be due to more than just the primary cancer — in contrast to what was widely believed — and that pain control should be based on careful assessment of pain to identify the most appropriate medical treatment, be it further surgery or medication. Robert Twycross [38] who conducted clinical research into pain at St. The Hospice provided a ready subset of patients for clinical trials, whilst the high standards of the purpose-built facility— matching those of the National Health Service — arguably added credence to any data that was published from the Hospice. -
Alcohol and Other Drugs: Realities for You and Your Family
DOCUMENT RESUME ED 469 036 CE 082 510 AUTHOR Corrigan, Mary TITLE Alcohol and Other Drugs: Realities for You and Your Family. Health Promotion for Adult Literacy Students: An Empowering Approach. INSTITUTION Hudson River. Center for Program Development, Glenmont, NY. SPONS AGENCY New York State Univ. System, Albany.; New York State Education Dept., Albany. Office of Workforce Preparation and Continuing Education. PUB DATE 1994-00-00 NOTE 107p.; Funded under Section 326 of the Adult Education Act. Contributing authors were Colleen Bodane and Robin Granger Rischbieter. AVAILABLE FROM For full text: http://www.hudrivctr.org/dnload.htm#alcoh. PUB TYPE Guides Classroom Teacher (052) EDRS PRICE EDRS Price MF01/PC05 Plus Postage. DESCRIPTORS Adult Basic Education; Adult Learning; *Adult Literacy; Adult Students; Counseling Services; Definitions; Evaluation Criteria; Family Problems; Family Violence; Fused Curriculum; Glossaries; Guidelines; *Health Promotion; Helping Relationship; Instructional Materials; *Integrated Curriculum; Learning Modules; Lesson Plans; *Literacy Education; Medical Services; National Organizations; Nonprofit Organizations; Prevention; Rehabilitation Programs; Risk; Self Evaluation (Individuals); Self Help Programs; Social Support Groups; *Student Empowerment; *Substance Abuse IDENTIFIERS *New York; Relapse ABSTRACT This document is a learning module designed to provide adult literacy practitioners in New York and elsewhere with the materials needed to take an empowering approach to helping adult literacy learners deal with the realities of alcohol and other drug issues affecting them and their families. The module includes background material, information on resources, and sample lesson plans for use by instructors themselves or by guest presenters. The document begins with reading materials on the following topics: the history of substance abuse; substance use versus nonuse; elements of risk; associated risks; prevention; treatment options; self-help programs; recovery; and substance abuse in others around us. -
Palliative Care Conference Faculty/Presenter Disclosure
Covenant Health’s 25th Annual Palliative Care Conference Faculty/Presenter Disclosure Presenter: Dr Nigel Sykes There are no relationships that pose a conflict of interest to declare AND this program has been developed without support from commercial entities. A Legacy of Pride and Progress 25th Annual Palliative Care Conference 2014 Palliative Care: Past, Present and Future Nigel Sykes St Christopher's Hospice London UK Where did Palliative Care come from? Hospice and Palliative Care began as a healthcare reform initiative inspired by: The perceived failure of existing cancer care The particular failure of doctors to deal adequately with dying patients At heart it has therefore always been medical in nature But to be effective it must be a social movement too “I want what is in your heart and what is in your mind” David Tasma Dame Cicely Saunders 1911-1948 1918-2005 Inspirer of the Founder of the modern hospice and palliative modern hospice and palliative care care movement movement St Christopher‟s Hospice 850 patients and families on any one day Services free to users 48 in-patient beds 900 admissions each year Serves a diverse population of 1.5 million people 15% non-malignancy Independent charity £19 million annual budget Hospice has Grown Up It gave rise to Palliative Care By 1975 (Balfour Mount, Montreal) It became a “Movement” By 1978 (Sandol Stoddard) It spread: Usually by inspiring dynamic individuals re- creating Hospice in locally adapted versions A strength? Not often by governments A weakness? It can save money -
50 Years of Research
50 Years of Research The fourth in a series of five conferences in 2017 reflecting on 50 years of UK hospice care evolution ONE DAY CONFERENCE Friday 15 September 2017 TIME 10am-4pm Registration from 9.30am COST £150 Organisations or individuals can purchase a series pass for £500 securing five places across the 50 Years of UK Hospice Care Evolution series. If the organisation owns the pass the attendees can be different members of staff and the number of places can be allocated as you’d like across the series. VENUE St Christopher’s Hospice, London CODE EVOL0917 St Christopher’s Education 50 Years of Research Since the early morphine studies it has been clear that, in order to replicate effective care across the sector, hospices must be underpinned by robust and relevant research. However, palliative and end of life care research has its unique challenges. How are hospices responding to these challenges and ensuring that our services and interventions are evidence based? Who is the conference for? Who are the speakers? This conference is for: Chair • any hospice or hospital palliative • Dr Heather Richardson Joint Chief care staff, especially senior clinicians, Executive, St Christopher’s; Honorary wanting to deliver evidence based Professor in the International services Observatory on End of Life Care at • hospice managers and Lancaster University • academics interested in how hospices Speakers might respond to current and future • Dr Sarah Russell Head of Research and challenges caused by increased and Clinical Innovation, Hospice UK changing demands on health and • Dr Robert Twycross Emeritus Clinical social care services. -
Rand Study Answers Some Questions About the Effects of Ppis
News Downloaded from https://academic.oup.com/ajhp/article/38/11/1635/5200642 by guest on 28 September 2021 Rand Study Answers Some Questions about the Effects of drug therapy are much affected hy receiving a PPI. Most PPis respondents elected to take the drug once they had pur chased it; only a few seem to have chrmged their decision as Patient package inserts (PPIs) fared well in an FDA-spon a result of the information they received. sored study of alternative designs by the Rand Corporation. The 5. The costs of returned prescriptions are likely to be quite low. Previous estimates of the annual cost of returned pre study showed that patients read and understand PPIs, do not scriptions that will result from FDA's proposed labeling report more side effects as a result of reading PPIs, and can ' program have been as high as $87.75 million—a figure based handle fairly lengthy and complex PPIs. on the assumption that for every 60 new prescriptions, PPIs will cause one additional prescription to he returned. These The Rand study was conducted from autumn 1979 through results indicate that this estimate is several orders of mag spring 1980 at 69 pharmacies in Los Angeles County, CA. Al nitude too high. During the course of the study, only three ternative PPIs were studied for three drugs: erythromycin, prescriptions were returned to pharmacies for cash refunds, conjugated estrogens, and flurazepam. Six variables of PPIs out of more than 2000 prescriptions dispensed with PPIs. Even if pharmacies were to pass on the full costsof returned were included: specificity of instructions, amount of explanation, pr^riptions to the consiuner, the resulting increases in drug writing style, risk emphasis, format, and reduced content prices would he extremely small. -
Psychotropic Drugs G
Postgrad Med J: first published as 10.1136/pgmj.60.710.881 on 1 December 1984. Downloaded from Postgraduate Medical Journal (December 1984) 60, 881-885 Psychotropic drugs G. W. HANKS B.Sc., M.B., M.R.C.P. The Royal Marsden Hospital, Fulham Road, London SW3 6JJ Introduction system-depressant effect ofthese drugs: by depressing the general level of arousal the central perception of The interaction between the cognitive component pain may be modified. (the perception ofnociceptive, or painful stimuli) and In this review the evidence for intrinsic analgesic the affective component of pain is reflected in the activity and overlap between the actions of anti-nociceptive the place of psychotropic drugs in the agents (analgesics) and mood-altering drugs (psycho- treatment of chronic pain are discussed in the light of tropics) when treating pain patients. Anxiety, depres- the published literature and recent clinical experi- sion, fear and sleeplessness may all respond to ence. psychotropic drugs, and this may result in a reduc- tion in pain or a greater ability to cope with it. This TABLE 1. The WHO classification of psychotropic drugs may enable a patient's pain to be controlled with a Neuroleptics by copyright. smaller dose of analgesic. In this sense psychotropic Anxiolytic sedatives drugs have an 'analgesic' effect but it is a misleading Antidepressants use of the word, and has been the source of much Psychostimulants misunderstanding. Psychodysleptics In the day-to-day management of pain problems the two groups of drugs do have well-defined indications. Acute pain is invariably associated with Neuroleptics nociception, and responds to analgesics or other Neuroleptics are antipsychotic agents of which the antinociceptive treatments. -
Cancer Pain Relief Since 1945, Using Sociological, Historical and Ethical Perspectives
Evaluation in cancer pain: from private to public trouble? Jane Seymour, University of Sheffield David Clark, Lancaster University Co-researchers: Michelle Winslow, Bill Noble, Fiona Graham, Silvia Paz, Henk ten Have, Marcia Meldrum Project aim and objectives Aim To analyse the global development of innovative technologies for cancer pain relief since 1945, using sociological, historical and ethical perspectives. Objectives To construct a narrative history of cancer pain relief since 1945, identifying key forms of technological innovation. To conduct two case studies of cancer pain innovation 1) the clinical domain 2) the public health domain identifying in each case ‘critical incidents’ of innovation and key drivers. Methods: see Final report to the ESRC, award no.: L218252055 Clark D et al www.regard.ac.uk Culture, technology and the cancer pain experience : the early days ‘I enquired why narcotics were not available for men and was told that men don’t need powerful drugs like that. It is hard to believe that such attitudes existed, but they did …it is worth recording that life was very bad sometimes for people with severe pain’[1] [1] Professor Sir Michael Bond, in: Reynolds LA and Tansey EM (eds) (2004) Wellcome Witnesses to Twentieth Century Medicine, Volume 21: Innovation in Pain Management. London: Wellcome Trust Centre for the History of Medicine at UCL, p21. Overview 1. The transformation of morphine from ‘last resort’ to ‘gold standard’ 2. A commercial space for innovation: new products and their evaluative criteria 3. New products and resource poor countries: the concept of ‘balance’ The transformation of morphine from ‘last resort’ to ‘gold standard’ Early changes • From liberal use in the early 20th century, to rapid regulation and moral panic about addiction: ‘…we are often loath to give liberal amounts of opiates because the drug addiction itself may become a hideous spectacle and actually result in great misery for the patient’[i], p8 [i] Cole W (1956) Foreword In: MJ Schiffin (ed) The Management of Pain in Cancer.